Suppr超能文献

血管紧张素 II 受体拮抗剂与钙通道阻滞剂或利尿剂联合用于慢性肾脏病患者的降压治疗。

Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.

机构信息

Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan.

出版信息

Clin Exp Hypertens. 2011;33(6):366-72. doi: 10.3109/10641963.2010.503299. Epub 2011 Jul 28.

Abstract

We compared treatment with an angiotensin II receptor antagonist (ARB) and a calcium channel blocker (CCB) combination and a fixed-dose ARB and thiazide diuretic in 18 chronic kidney disease (CKD) patients. A randomized crossover study was performed using a fixed-dose combination of losartan-hydrochlorothiazide or losartan combined with controlled-release nifedipine. Both systolic blood pressure (SBP) and diastolic blood pressures (DBPs) were lower during the nifedipine period than during the diuretic period. No significant difference was observed in urinary albumin excretion, but the estimated glomerular filtration rate was higher in the nifedipine than in the diuretic period. Serum uric acid and low-density lipoprotein cholesterol were higher in the diuretic than in the nifedipine period. A significantly low cardio-ankle vascular index, an index of arterial wall stiffness, was observed in the nifedipine period. A combination of ARB and a controlled-release nifedipine at 20-40 mg used showed a superior antihypertensive effect in CKD patients compared to a fixed-dose combination of losartan 50 mg-hydrochlorothiazide 12.5 mg in terms of blood control. The former combination is considered advantageous for maintaining renal function and artery wall elasticity without influencing uric acid or lipid metabolism.

摘要

我们比较了血管紧张素 II 受体拮抗剂 (ARB) 和钙通道阻滞剂 (CCB) 联合治疗与固定剂量 ARB 和噻嗪类利尿剂在 18 例慢性肾脏病 (CKD) 患者中的疗效。采用氯沙坦-氢氯噻嗪固定剂量联合制剂或氯沙坦与控释硝苯地平联合进行随机交叉研究。硝苯地平治疗期间的收缩压 (SBP) 和舒张压 (DBP) 均低于利尿剂治疗期间。尿白蛋白排泄量无显著差异,但估计肾小球滤过率在硝苯地平治疗期间高于利尿剂治疗期间。血清尿酸和低密度脂蛋白胆固醇在利尿剂治疗期间高于硝苯地平治疗期间。硝苯地平治疗期间观察到心血管踝血管指数(动脉壁僵硬指数)显著降低。与使用氯沙坦 50 mg-氢氯噻嗪 12.5 mg 的固定剂量联合制剂相比,20-40 mg 的 ARB 和控释硝苯地平联合治疗在控制血压方面对 CKD 患者显示出更好的降压效果。前者的联合治疗被认为有利于维持肾功能和动脉壁弹性,而不会影响尿酸或脂质代谢。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验